Fig. 3From: Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm studySubgroup analysis of ORR. The dotted line indicates the null hypothesis of ≤15% for the ORR reported in this studyBack to article page